Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study.

Searles G, Bissonnette R, Landells I, Shear NH, Papp K, Lui H.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S131-8.

PMID:
20053325
2.

Efficacy outcomes in patients using alefacept in the AWARE study.

Landells I, Searles G, Bissonnette R, Shear NH, Vender R, Lui H.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S122-30.

PMID:
20053324
3.

The AWARE study: methodology and baseline characteristics.

Bissonnette R, Searles G, Landells I, Shear NH, Papp K, Lui H, Gulliver WP, Lynde C.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S113-21.

PMID:
20053323
4.

Update on alefacept safety.

Wexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, Poulin Y, Langley R, Gulliver WP.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S139-47.

PMID:
20053326
5.

A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.

Krueger GG, Gottlieb AB, Sterry W, Korman N, Van De Kerkhof P.

J Dermatolog Treat. 2008;19(3):146-55. doi: 10.1080/09546630701846103.

PMID:
18569270
6.

The next phase of real-world clinical experience with alefacept: the AWARE-2 registry.

Searles G, Bissonnette R, Landells I, Shear NH.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S148-52. No abstract available.

PMID:
20053327
7.

An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.

Ortonne JP, Khemis A, Koo JY, Choi J.

J Eur Acad Dermatol Venereol. 2005 Sep;19(5):556-63.

PMID:
16164708
8.

Preface: real-world clinical experience with alefacept-the Amevive Wisdom Acquired from Real-World Evidence (AWARE) study.

Searles G, Bissonnette R, Landells I, Shear NH.

J Cutan Med Surg. 2009 Dec;13 Suppl 3:S107-12. Review. No abstract available.

PMID:
20053322
9.

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN; Alefacept Clinical Study Group.

J Am Acad Dermatol. 2002 Dec;47(6):821-33.

PMID:
12451365
11.
12.
13.

Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis.

Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, Wolf P.

Arch Dermatol. 2007 Aug;143(8):1016-22.

PMID:
17709660
14.

The added therapeutic efficacy and safety of alefacept in combination with other (systemic) anti-psoriatics in refractory psoriasis.

Langewouters AM, Van Erp PE, De Jong EM, Van De Kerkhof PC.

J Dermatolog Treat. 2006;17(6):362-9.

PMID:
17853311
15.

The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.

Langewouters AM, Bovenschen HJ, De jong EM, Van Erp PE, Van De Kerkhof PC.

J Dermatolog Treat. 2007;18(5):279-85.

PMID:
17852631
16.

Clinical update on alefacept: consideration for use in patients with psoriasis.

Gade JN.

J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S33-7. Review.

PMID:
15253688
18.

Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.

Perlmutter A, Cather J, Franks B, Jaracz E, Menter A.

J Am Acad Dermatol. 2008 Jan;58(1):116-24. Epub 2007 Nov 12.

PMID:
17997502
20.

Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.

Bovenschen HJ, Gerritsen WJ, van Rens DW, Seyger MM, de Jong EM, van de Kerkhof PC.

Arch Dermatol Res. 2007 Feb;298(9):457-63. Epub 2006 Nov 30.

PMID:
17136563

Supplemental Content

Support Center